Namenda
Product Images NDC 21695-169

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Namenda (NDC 21695-169). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Namenda Chemical Structure (74ce605d B493 4b95 9d59 9253f81f4e20 01)

Chemical structure of memantine hydrochloride, the active ingredient in Namenda, shown as a molecular diagram with labeled chemical groups NH2 and CH3, and HCl indicating the hydrochloride salt form.*

FDA Label Image

Image Of Figure 1: Time Course Of Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 02)

A line graph depicting the mean change from baseline in ADCS-ADL score over 28 weeks of treatment, comparing Namenda and placebo. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change with clinical improvement and decline marked. Namenda shows less decline compared to placebo over time.*

FDA Label Image

Image Of Figure 2: Cumalative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 03)

A cumulative percentage of patients chart comparing NAMENDA to placebo, showing the ADCS-ADL change from baseline on the x-axis and cumulative percentage of patients on the y-axis. NAMENDA data points are marked with circles, placebo with squares, illustrating differences in patient outcomes.*

FDA Label Image

Image Of Figure 3: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 04)

A line graph depicting mean change from baseline in SIB Score over 28 weeks of treatment, comparing Namenda and placebo groups. The x-axis shows weeks of treatment, and the y-axis shows mean (± SEM) change in SIB score. The graph includes markers for clinical improvement and clinical decline, illustrating treatment effects over time.*

FDA Label Image

Image Of Figure 4: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 05)

A line graph comparing cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline for Namenda and placebo groups. The x-axis shows SIB change values from approximately 15 to -30, and the y-axis shows the cumulative percentage of patients from 0 to 100%. The Namenda group is represented by an open circle line, showing higher cumulative percentages for larger negative SIB changes compared to the placebo group, which is depicted with a filled square line.*

FDA Label Image

Image Of Figure 5: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 06)

A line graph comparing NAMENDA/Donepezil and Placebo/Donepezil over 24 weeks of treatment, showing mean change from baseline in ADCS-ADL score with error bars. The vertical axis ranges from clinical improvement to clinical decline, while the horizontal axis shows weeks of treatment from 0 to 24.*

FDA Label Image

Image Of Figure 6: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 07)

A line graph showing the cumulative percentage of patients versus ADCS-ADL change from baseline for two treatment groups: Placebo/Donepezil and Namenda/Donepezil. The graph compares the distribution of patient responses across ADCS-ADL change values for both groups.*

FDA Label Image

Image Of Figure 7: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 08)

A line graph comparing clinical effects measured by mean change in SIB scores over 24 weeks of treatment between Namenda/Donepezil and Placebo/Donepezil groups. The y-axis shows mean change from baseline, with positive scores indicating clinical improvement and negative scores indicating clinical decline, while the x-axis indicates weeks of treatment.*

FDA Label Image

Image Of Figure 8: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 09)

A cumulative percentage graph comparing patients' SIB (Severe Impairment Battery) change from baseline between Placebo/Donepezil and NAMENDA/Donepezil groups. The x-axis represents SIB change values, and the y-axis shows the cumulative percentage of patients. The graph indicates higher cumulative improvement in the NAMENDA/Donepezil group versus Placebo/Donepezil.*

FDA Label Image

Namenda 10mg (74ce605d B493 4b95 9d59 9253f81f4e20 10)

Label for Namenda 10 mg tablets with a package size of 60 tablets, containing the active ingredient memantine hydrochloride. The label features the Physician Partner logo, includes lot and expiration placeholders, and states the product manufacturer as Forest Laboratories Inc., St. Louis, MO. It also includes storage instructions and warnings.*

FDA Label Image

Namenda 5mg (74ce605d B493 4b95 9d59 9253f81f4e20 11)

Namenda 5 mg tablets label from Rebel Distributors Corp, showing the product as memantine 5 mg tablets in a quantity of 60. The label includes usage details, the NDC number 21695-232-60, and manufacturer information from Forest Laboratories Inc., St. Louis, MO. It also has storage instructions and caution to keep medication out of the reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.